The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER+) breast cancer, considering five interacting resistance pathways.
Given the frequent Tamoxifen treatment failure, resistance prevention and reversal is an urgent clinical problem that is central in EpiPredict. The EpiPredict intersectorial training programme employs a timely systems medicine approach combining next-generation systematic epigenetic, gene/protein profiling with innovative gene-specific epigenetic interference technologies and computational modelling. Together the ESRs will identify key epigenetic changes underlying Tamoxifen induced resistance providing an important step towards diagnostic markers/tools to predict treatment outcome/response monitoring.
The fellows will be trained in research-specific AND complementary skills by experts from 6 academic and 2 non-academic beneficiaries and 7 partner organizations (1 academic, 6 non-academic including industrial/socio-public parties) and 5 visiting scientists.
Strong involvement of the private sector ensures exploitation of EpiPredict achievements and exposure to an entrepreneurial mindset. These supradisciplinary fellows will master and apply urgently needed new approaches to address complex diseases taking personalized patient aspects into consideration being equipped to succeed in their careers providing extra impulses to drive European translational science and systems medic
The project works on epigenetic research into resistance to endocrine (hormonal) therapy in breast cancer. The possibility to predict and avoid resistance to endocrine therapy will be a step closer to achieving a so called tailored therapy for breast cancer patients.